arrow
K

Kunihiko Tsuji

teine keijinkai hospital
H指数:39
被引数:5,172

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort study

代谢功能障碍对核苷(酸)类似物治疗慢性乙型肝炎反应的影响:一项回顾性多中心REAL-B队列研究

2025-08-110
PREAI
Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab-Treated HCC
2025-01-220
PRE
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab

不良事件是晚期HCC患者接受阿特珠单抗联合贝伐单抗治疗的潜在预测因素

2024-04-301
OAAI
Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents

开发直接抗病毒药物后,日本丙型肝炎病毒引起的肝细胞癌患者临床结局的变化

2024-04-112
PRE
Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study
2024-04-106
OAAI
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab

体重指数对接受一线乐伐替尼或阿特珠单抗联合贝伐单抗治疗的不可切除HCC患者预后的影响

2024-03-222
PRE
Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma
2024-01-300
PRE
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma

Lenvatinib在高龄不可切除的肝细胞癌患者中的安全性和有效性

2024-01-222
PRE
Regional Differences in Clinical Presentation and Prognosis of Patients With Post-Sustained Virologic Response Hepatocellular Carcinoma
2024-01-012
OA
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

Α-fate: 阿特珠单抗联合贝伐单抗治疗不可切除肝细胞癌的新预测评分

2023-11-238
PRE
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma

阿特珠单抗联合贝伐单抗与来伐替尼对中晚期肝细胞癌患者预后影响的比较

2023-10-033
OA
Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varices

阿特珠单抗联合贝伐单抗治疗不可切除肝癌伴食管胃底静脉曲张患者的疗效和安全性

2023-08-013
PRE
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

肝细胞癌患者阿特珠单抗联合贝伐单抗或来伐替尼一线治疗后的序贯疗法

2023-08-0128
OA
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab

老年营养风险指数作为一种易于使用的评估工具,用于评估接受阿特珠单抗联合贝伐单抗治疗的肝细胞癌的营养状况

2023-06-2814
OAAI
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma

阿特珠单抗联合贝伐单抗一线全身治疗对肝细胞癌患者的影响

2023-05-253
PRE
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis

质子泵抑制剂和抗生素使用与接受阿特珠单抗和贝伐单抗的肝细胞癌患者临床结局的关系: 多中心分析

2023-04-183
PRE
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?

阿特珠单抗联合贝伐单抗治疗不可切除肝细胞癌的真实世界数据: 依从IMbrave150试验纳入标准如何影响预后?

2023-03-1514
PRE
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Atezolizumab联合贝伐单抗与lenvatinib治疗不可切除的肝细胞癌: 大量现实世界人口

2023-02-0176
PRE
Relationship of atezolizumab plus bevacizumab treatment with muscle volume loss in unresectable hepatocellular carcinoma patients- multicenter analysis

阿特珠单抗联合贝伐单抗治疗与不可切除肝细胞癌患者肌肉体积丢失的关系 -- 多中心分析

2022-12-087
OAAI